Core Viewpoint - The Australian carrier has agreed to settle a class action lawsuit regarding its policy of not providing immediate cash refunds for flights canceled during the Covid-19 pandemic [1] Group 1 - The settlement addresses customer grievances related to the airline's refund practices during the pandemic [1] - The decision reflects the ongoing legal and financial implications faced by airlines due to the pandemic [1]

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. by investors [1] Group 1 - The lawsuit is being handled by Pomerantz LLP, which is advising affected investors to contact them for further information [1] - The company is listed on NASDAQ under the ticker symbol AQST [1]

Market Overview - The current market is experiencing significant downturns, with the Dow dropping 739 points, the S&P falling 1.52%, and the Nasdaq decreasing by 1.78% due to rising oil prices influenced by ongoing geopolitical tensions [3][4]. Oil Market Dynamics - Oil prices are expected to rise significantly, potentially reaching $200 per barrel, as Iran utilizes drones to target oil infrastructure in the Gulf region, creating vulnerabilities in oil supply [5][6]. - The geopolitical situation allows Iran to profit from high oil prices while maintaining a strategic advantage by blocking shipping routes [6][12]. Investment Sentiment - Many investors are feeling bearish, leading to increased short positions in the market, particularly among hedge funds that are not benefiting from oil stocks [7][8]. - Despite the negative sentiment, the market is showing signs of being oversold, with the S&P oscillator indicating a rare minus 7.5%, suggesting potential for a market rebound [8][19]. Political Implications - The U.S. administration may seek to negotiate a resolution to the conflict, which could lead to a significant drop in oil prices and a subsequent market rally if a ceasefire is achieved [10][11]. - The current administration's willingness to adapt strategies in response to market conditions could influence future market performance [9][11]. Long-term Outlook - Historically, markets have rebounded after downturns, and investors are encouraged to remain in the market to capitalize on potential gains once the geopolitical situation stabilizes [18][19]. - The current economic conditions, while challenging, are not as severe as past financial crises, suggesting that maintaining investment positions could be beneficial in the long run [17][18].

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Driven Brands Holdings Inc. (Driven Brands) (NASDAQ: DRVN) on behalf of those who purchased or acquired Driven Brands common stock between May 9, 2023, and February 24, 2026, inclusive. The lawsuit is filed in the United States District Court for the Southern District of. ...

Group 1 - The tech giant has delayed its timeline for advancements in artificial intelligence after investing billions to maintain a competitive edge in the industry [1]

Core Viewpoint - A class action lawsuit has been filed against Trip.com Group Limited due to allegations of securities fraud and unlawful business practices, with a significant drop in its stock price following antitrust investigations in China [1][1][1] Group 1: Legal Actions - The class action lawsuit is initiated by Pomerantz LLP, advising affected investors to contact them for participation [1][1] - Investors have until May 11, 2026, to request appointment as Lead Plaintiff if they acquired Trip.com securities during the Class Period [1][1] Group 2: Regulatory Issues - Trip.com is under investigation by China's State Administration for Market Regulation for alleged antitrust conduct, accused of monopolistic practices [1][1] - The company faced prior scrutiny in September 2025 for imposing unfair restrictions on merchants' transactions and pricing [1][1] Group 3: Market Impact - Following the news of the antitrust investigation, Trip.com's American Depositary Receipt (ADR) price fell by $12.90, or 17.05%, closing at $62.78 on January 14, 2026 [1][1][1]

Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for alleged misconduct related to the purchase of its common stock during a specified period [1] Group 1: Lawsuit Details - The lawsuit is filed on behalf of investors who purchased or acquired Soleno common stock between March 26, 2025, and November 4, 2025 [1] - The case is being heard in the United States District Court for the Northern District of California [1]

Core Insights - Runway Growth Finance Corp. reported a revenue of $30.04 million for the quarter ended December 2025, reflecting an 11.1% decrease year-over-year and falling short of the Zacks Consensus Estimate of $32.19 million by 6.69% [1] - The company's earnings per share (EPS) was $0.32, down from $0.39 in the same quarter last year, and also below the consensus estimate of $0.36, resulting in an EPS surprise of -11.11% [1] Financial Performance - Investment income from non-control/non-affiliate sources included interest income of $25.66 million, which was lower than the average estimate of $27.04 million from two analysts [4] - Dividend income matched the estimate at $0.25 million, while payment in-kind interest income was reported at $4.31 million, slightly above the average estimate of $4.17 million [4] Stock Performance - Over the past month, shares of Runway Growth Finance Corp. have declined by 16.9%, contrasting with a 2.3% decrease in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Jefferson Capital, Inc. (JCAP) reported revenue of $154.8 million for the quarter ended December 2025, showing no change compared to the same period last year [1] - The company's EPS was $0.58, an increase from $0 in the year-ago quarter [1] - Revenue fell short of the Zacks Consensus Estimate of $158.49 million, resulting in a surprise of -2.33% [1] - The EPS also missed the consensus estimate of $0.71, leading to an EPS surprise of -18.31% [1] Financial Performance Metrics - Total collections for the quarter were $245.3 million, exceeding the two-analyst average estimate of $238.25 million [4] - Servicing revenue was reported at $9.06 million, slightly below the two-analyst average estimate of $9.46 million [4] - Total portfolio revenue was $144 million, which was lower than the two-analyst average estimate of $147.35 million [4] Stock Performance - Over the past month, shares of Jefferson Capital, Inc. have returned -5.9%, compared to a -2.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

分组1 - The Joint Corp. reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, with an earnings surprise of +33.33% [1] - The company achieved revenues of $15.17 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 10.59% and showing an increase from $14.45 million year-over-year [2] - The Joint has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] 分组2 - The stock has underperformed the market, losing about 2.4% since the beginning of the year compared to a 1% decline in the S&P 500 [3] - The current consensus EPS estimate for the coming quarter is $0.15 on $14 million in revenues, and for the current fiscal year, it is $0.57 on $55.41 million in revenues [7] - The Zacks Industry Rank for Medical - HMOs is currently in the bottom 9% of over 250 Zacks industries, indicating potential challenges for stock performance [8]